Allogene Therapeutics, Inc. (ALLO)
2.12
-0.02
(-0.93%)
USD |
NASDAQ |
May 15, 09:35
Allogene Therapeutics Shareholders Equity (Quarterly) : 278.88M for March 31, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Agenus, Inc. | -221.22M |
| Inovio Pharmaceuticals, Inc. | 6.068M |
| Vaxart, Inc. | 94.12M |
| Capricor Therapeutics, Inc. | 278.70M |
| Curis, Inc. | 12.71M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 395.96M |
| Total Liabilities (Quarterly) | 117.08M |
| Debt to Equity Ratio | 0.2906 |
| Current Ratio | 9.647 |
| Net Debt Paydown Yield | 0.33% |